Table 1– Demographics and baseline characteristics
PlaceboQVA149 110/50 μgIndacaterol 150 μgGlycopyrronium 50 μgTiotropium 18 μg
Subjects n232474476473480
Age years64.4±8.664.0±8.963.6±8.864.3±9.063.5±8.7
Male169 (72.8)362 (76.4)354 (74.4)365 (77.2)360 (75.0)
Race
 Caucasian155 (66.8)321 (67.7)332 (69.7)315 (66.6)322 (67.1)
 Asian71 (30.6)140 (29.5)131 (27.5)137 (29.0)135 (28.1)
 Other6 (2.6)13 (2.7)13 (2.7)21 (4.4)23 (4.8)
Duration of COPD years6.4±5.76.0±5.56.3±5.66.5±5.86.1±5.5
COPD severity
 Moderate157 (67.7)313 (66.0)294 (61.8)298 (63.0)296 (61.7)
 Severe75 (32.3)161 (34.0)182 (38.2)173 (36.6)184 (38.3)
ICS use134 (57.8)268 (56.5)269 (56.5)274 (57.9)282 (58.8)
Smoking status
 Ex-smoker139 (59.9)282 (59.5)292 (61.3)284 (60.0)291 (60.6)
 Current smoker93 (40.1)192 (40.5)184 (38.7)189 (40.0)189 (39.4)
COPD exacerbation history#
 0184 (79.3)352 (74.3)348 (73.1)346 (73.2)363 (75.6)
 137 (15.9)94 (19.8)106 (22.3)91 (19.2)93 (19.4)
 ≥211 (4.7)28 (5.9)22 (4.6)36 (7.6)24 (5.0)
Pre-bronchodilator FEV1 L1.3±0.51.3±0.51.3±0.51.3±0.51.3±0.5
Post-bronchodilator FEV1 L1.5±0.51.5±0.51.5±0.51.5±0.51.5±0.5
Post-bronchodilator FEV1 % pred55.2±12.755.7±13.254.9±12.955.1±13.455.1±13.5
Post-bronchodilator FEV1 reversibility %19.3±15.920.4±16.820.5±16.820.0±17.620.6±17.5
Post-bronchodilator FEV1/FVC %48.6±10.449.1±10.148.4±10.648.2±10.949.2±10.8
  • Data are presented as mean±sd or n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroids; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity. #: events in the previous year.